VI
PHAT icon

Versor Investments’s Phathom Pharmaceuticals PHAT Stock Holding History

Versor Investments’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,400
Closed -$101K – 900
2024
Q4 		$101K Buy
+12,400
New +$154K 0.02% 714

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Versor Investments's PHAT Position: Q1 2025 in Review

Versor Investments sold out of Phathom Pharmaceuticals (PHAT) in Q1 2025, closing a stake of 12,400 shares — an estimated $101K sold.

Versor Investments first reported a position in PHAT in Q4 2024 and held it in 1 quarter. The position peaked at $101K in Q4 2024. 137 funds tracked by Wall St. Rank hold PHAT as of Q1 2025.

  • Versor Investments reported no remaining Phathom Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Versor Investments sold 12,400 Phathom Pharmaceuticals shares in Q1 2025, an estimated $101K.
  • Versor Investments first reported a position in Phathom Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Versor Investments's Phathom Pharmaceuticals position peaked at $101K in Q4 2024.
  • 137 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2025.

Based on Versor Investments's 13F filing for Q1 2025, filed 13 May 2025.